copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
DURECT | Unlocking the potential of epigenetic therapeutics DURECT harnesses epigenetic modulation to potentially treat serious and life-threatening conditions, including acute organ injury and cancer Our unique approach targeting dysregulated DNA methylation has the potential to change the course of disease and improve patients’ lives
Investors - DURECT DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer
About Us | DURECT We’re advancing a novel therapeutic approach by harnessing the power of epigenetic regulation
DURECT Corporation (DRRX) - Yahoo Finance See the company profile for DURECT Corporation (DRRX) including business summary, industry sector information, number of employees, business summary, corporate governance, key executives and
News - DURECT DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation (DRRX) - Yahoo Finance Find the latest DURECT Corporation (DRRX) stock quote, history, news and other vital information to help you with your stock trading and investing